Biocom’s Statement in Response to the Resignation of FDA Commissioner Margaret Hamburg

SAN DIEGO — February 5, 2015 — Today, Biocom, the association representing the Southern California life science community, issued the following statement in response to the news that Margaret Hamburg, M.D. will be resigning as FDA Commissioner, effective the end of March, 2015.

“Biocom commends Commissioner Margaret Hamburg on her remarkable tenure at the Food and Drug Administration. Dr. Hamburg has been one of the most effective commissioners in the history of the FDA, leading the agency into the 21st Century and shaping a new era of medicine,” said Joe Panetta, President and CEO of Biocom.

“Dr. Hamburg has been a leader, a visionary, and a friend, who will be remembered for her unparalleled commitment to improving our regulatory environment and her openness to working in concert with stakeholders. Under her tenure, Biocom and its members have enjoyed significantly improved access to the agency and its Centers’ Directors, which has helped advance the development of new drugs and devices, while maintaining the world’s strictest standards for patient safety.”

“Biocom thanks the Commissioner for her service and many accomplishments, and looks forward to working with her successor to continue improving the drug, device and, diagnostics approval process and bring life-enhancing and life-saving innovations to patients.”

About Biocom

Biocom is one of the largest regional life science associations in the world, representing more than 660 member companies in Southern California. The association focuses on initiatives that position the region’s life science industry competitively on the world stage, and on the development and delivery of innovative products that improve health and quality of life. For more information on Biocom or the Southern California biotechnology and medical device community, please visit the organization’s Web site at http://www.biocom.org or call (858) 455-0300.